Chiara Rosso
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · 320 works · 7,935 citations · h-index 43
Top works
- Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
- Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
- Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
- Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
- Mobilization of Cytogenetically ‘Normal’ Blood Progenitors Cells by Intensive Conventional Chemotherapy for Chronic Myeloid and Acute Lymphoblastic Leukemia
- Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
- Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
- Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
- Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
- MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
- Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
- Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
- Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
- An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
- MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
- The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease
- Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis
- Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
- Inhibition of c-myc Expression Induced by 4-Hydroxynonenal, a Product of Lipid Peroxidation, in the HL-60 Human Leukemic Cell Line